Abbott's Leadless Pacemaker Drives Sales Growth

Abbott Laboratories' cardiac rhythm management (CRM) business achieved a significant 10% sales increase in the second quarter, the company announced. Growth is attributed to the accelerated adoption of the company's AVEIR™ leadless pacemaker system, which has transformed treatment for patients requiring pacing.

The FDA approval of the company's dual-chamber (DR) system, along with the atrial (AR) device in 2023, marked a turning point for the CRM business. Leadless pacemakers are implanted directly into the heart through a minimally invasive procedure, eliminating the need for cardiac leads. This reduces lead-related complications and speeds up recovery.

The success of the AVEIR system is helping the company capture share in the fast-growing leadless pacemaker market. Abbott is the only company offering atrial leadless pacing. According to the company, its CRM business previously saw single-digit growth, but thanks to AVEIR's uptake, it has achieved a double-digit growth rate now considered sustainable.

Abbott continues to invest in research and development. The company is introducing a next-generation atrial device with a 25% longer battery life. Based on study results, the company plans to initiate a pivotal trial for a leadless pacemaker for physiologic pacing next year.